Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Arrowhead Pharmaceuticals Inc. (ARWR) Tops Q1 EPS by 10c
February 5, 2026 4:11 PM ESTArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q1 EPS of $0.22, $0.10 better than the analyst estimate of $0.12. Revenue for the quarter came in at $264.03 million versus the consensus estimate of $227.61 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
... More